Medical technology company Phase Holographic Imaging (PHI) announced on Tuesday that it is advancing its next-generation live cell imaging system to the final development stage.
The new HoloMonitor CellSync model is undergoing pre-production testing at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine. This system represents the first in a series aimed at establishing a new standard in automated quality control for cell and gene therapy manufacturing. Future models will integrate cutting-edge image processing and artificial intelligence technologies.
Manufactured according to ISO 9001 standards, the HoloMonitor CellSync enhances PHI's imaging technology with a new camera module and improved automated cell segmentation. These advancements have been refined over the past two years. The HoloMonitor CellSync is slated for release in the second half of 2025.
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Johnson & Johnson reports TAR-200 monotherapy study data in bladder cancer
InnoCare receives NMPA approval for orelabrutinib as first-line treatment for CLL/SLL in China
RaySearch Laboratories announces order from Odense University Hospital for RayStation
Guardant Health and Pfizer enter global collaboration to advance cancer therapy development
Adcendo to present clinical stage ADC data at 2025 AACR Annual Meeting
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Atossa Therapeutics secures new US patent for (Z)-endoxifen formulations